Esperion Therapeutics (ESPR) 2025 Conference Transcript

Esperion Therapeutics (ESPR) 2025 Conference May 08, 2025 12:30 PM ET Speaker0 I guess take a step back and Primary. I guess take a step back and go go through the data that went into those new labels. Can you just walk us through the clear outcome study and the findings there? Speaker1 So the clear outcome study was a 14,000 patient outcome study which measured MACE four, MACE three in a variety of endpoints in both a, in a non statin population in both a primary and secondary prevention patient population ...